NCT06251024已完成2 期
A Phase IIb, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an RSV Vaccine Candidate in Adult Participants 60 Years and Older
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 4,541
- 试验地点
- 25
- 主要终点
- Presence of the first episode of RSV-LRTD (RSV A and/or RSV B) ≥ 14 days after vaccination
研究概览
简要总结
The purpose of this Phase IIb study is to evaluate the efficacy of the RSV vaccine candidate for the prevention of lower respiratory tract disease (LRTD) due to RSV.
The study will enroll approximately 4500 adults aged 60 years and older in a 1:1 ratio to receive a single intra-muscular (IM) administration of either a pre-determined dose of the RSV vaccine candidate or placebo.
详细描述
Study duration per participant:
6 months.
Treatment Duration:
1 IM injection. Participants will be followed for approximately 6 months post- vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
- Investigators, laboratory personnel, sponsor and participants will be blinded
- Study staff preparing/administering the study interventions will be unblinded
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 60 years or older on the day of inclusion
- •A female participant is eligible to participate if she is not pregnant or breastfeeding and:
- •Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year or surgically sterile.
- •Participants with high-risk medical conditions who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion.
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol, polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances ;any allergic reaction (eg, anaphylaxis) after administration of an mRNA vaccine
- •History of RSV-associated illness, diagnosed clinically, serologically, or microbiologically in the last 12 months
- •Previous history of myocarditis, pericarditis, and/or myopericarditis
- •Thrombocytopenia, contraindicating IM injection based on investigator's judgment
- •Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM injection
- •Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
- •Alcohol, prescription drug, or substance abuse that, in the opinion of the investigator, might interfere with the study conduct or completion
- •Receipt of any vaccine in the 4 weeks preceding any study intervention administration or planned receipt of any vaccine in the 4 weeks following any study intervention administration
- •Receipt of any mRNA vaccine in the 60 days preceding any study intervention administration or planned receipt of any mRNA vaccine in the 60 days following any study intervention administration
- •Previous vaccination against RSV with a licensed or investigational vaccine or planned receipt during study participation, of vaccination against RSV with a licensed or investigational vaccine other than the study vaccine
- •Receipt of immune globulins, blood, or blood-derived products in the past 3 months
- •Participation at the time of study enrollment (or in the 4 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure Note: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
Group 1: RSV vaccine candidate
Experimental
Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the RSV vaccine candidate.
干预措施: RSV vaccine candidate (Biological)
Group 2: placebo
Placebo Comparator
Participants will be enrolled in a 1:1 ratio to receive a single IM administration of the placebo.
干预措施: Placebo (Biological)
结局指标
主要结局
Presence of the first episode of RSV-LRTD (RSV A and/or RSV B) ≥ 14 days after vaccination
时间窗: ≥ 14 days after vaccination
Number of participants experiencing RSV-LRTD (RSV A and/or RSV B) ≥ 14 days after vaccination
次要结局
- Presence of hospitalization due to RSV-ARD and/or RSV-LRTD(≥ 14 days after vaccination)
- Presence of the first episode of RSV MAARD (RSV A and/or RSV B) ≥ 14 days after vaccination(≥ 14 days after vaccination)
- Presence of the first episode of RSV LRTD (RSV A and/or RSV B and by each one) by baseline frailty status(≥ 14 days after vaccination)
- Presence of the first episode of RSV-ARD (RSV A and/or RSV B) ≥ 14 days after vaccination(≥ 14 days after vaccination)
- Presence of the first episode of RSV LRTD (RSV B) occurring ≥ 14 days after vaccination(≥ 14 days after vaccination)
- RSV A serum neutralizing antibodies (nAb) titers at pre vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset(Day 1 and Day 29)
- Presence of the first episode of RSV-LRTD (RSV A and/or RSV B and by each one) by age group(≥ 14 days after vaccination)
- Presence of the first episode of severe RSV LRTD (RSV A and/or RSV B and by each one) occurring ≥ 14 days after vaccination(≥ 14 days after vaccination)
- RSV A serum nAb titers at 6 months post-vaccination in the Immunogenicity Subset(Month 6)
- Presence of solicited injection site or systemic reactions(Within 7 days after primary vaccination)
- Presence of the first episode of RSV LRTD (RSV A) occurring ≥ 14 days after vaccination)(≥ 14 days after vaccination)
- Presence of the first episode of RSV LRTD (RSV A and/or RSV B and by each one) by baseline comorbidities(≥ 14 days after vaccination)
- Serum anti-F IgG Ab titers at 6 months post-vaccination in the Immunogenicity Subset(Month 6)
- Presence of unsolicited immediate systemic adverse events (AEs)(Within 30 minutes after primary vaccination)
- Presence of unsolicited AEs(Within 28 days after primary vaccination)
- Duration (number of days) of RSV LRTD episodes (RSV A and/or RSV B)(≥ 14 days after vaccination)
- Duration (number of days) of RSV ARD episodes (RSV A and/or RSV B)(≥ 14 days after vaccination)
- RSV B serum nAb titers at pre vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset(Day 1 and Day 29)
- Serum anti-F immunoglobulin G (IgG) antibody (Ab) titers at pre-vaccination (D01) and 28 days (D29) post vaccination in the Immunogenicity Subset(Day 1 and Day 29)
- Presence of serious adverse events (SAEs)(Throughout study (approximately 6 months))
- RSV B serum nAb titers at 6 months post-vaccination in the Immunogenicity Subset(Month 6)
- Presence of medically attended adverse events (MAAEs)(Throughout study (approximately 6 months))
- Presence of adverse events of special interest (AESIs)(Throughout study (approximately 6 months))
研究者
研究点 (25)
Loading locations...
相似试验
已完成
2 期
A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMENRespiratory Tract InfectionNCT04032093Pfizer1,153
已完成
2 期
A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARSRespiratory Tract InfectionNCT04071158Pfizer713
已完成
2 期
Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly AdultsRespiratory Syncytial Virus (RSV)NCT02266628Novavax1,599
已完成
1 期
Recombinant, Bivalent, Norovirus Vaccine StudyNorovirusNCT05508178Icon Genetics GmbH60
已完成
1 期
Evaluation of RSV/Flu-01E Vaccine for the Prevention of RSV Infection in Volunteers Aged 18 to 59 Years and Over 60 YearsRespiratory Syncytial Virus InfectionsNCT05970744Tatyana Zubkova60